ReproCELL (4978) Stock Overview
Provides stem cell research and drug discovery services in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
4978 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
ReproCELL Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥159.00 |
| 52 Week High | JP¥242.00 |
| 52 Week Low | JP¥112.00 |
| Beta | 0.57 |
| 1 Month Change | 4.61% |
| 3 Month Change | -5.36% |
| 1 Year Change | -20.10% |
| 3 Year Change | -43.01% |
| 5 Year Change | -62.41% |
| Change since IPO | -89.43% |
Recent News & Updates
Recent updates
Lacklustre Performance Is Driving ReproCELL Incorporated's (TSE:4978) Low P/S
Jan 15
ReproCELL Incorporated (TSE:4978) Shares Fly 26% But Investors Aren't Buying For Growth
Jul 25Here's Why We're Not Too Worried About ReproCELL's (TSE:4978) Cash Burn Situation
May 15The Market Doesn't Like What It Sees From ReproCELL Incorporated's (TSE:4978) Revenues Yet As Shares Tumble 28%
Apr 07ReproCELL Incorporated's (TSE:4978) Price Is Right But Growth Is Lacking
Jan 28ReproCELL Incorporated (TSE:4978) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough
Aug 05Here's Why We're Not Too Worried About ReproCELL's (TSE:4978) Cash Burn Situation
Jul 17Update: ReproCELL (TYO:4978) Stock Gained 33% In The Last Five Years
Feb 07
Shareholder Returns
| 4978 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | 0% | -0.7% | 3.4% |
| 1Y | -20.1% | 0.5% | 34.0% |
Return vs Industry: 4978 underperformed the JP Biotechs industry which returned 0.5% over the past year.
Return vs Market: 4978 underperformed the JP Market which returned 34% over the past year.
Price Volatility
| 4978 volatility | |
|---|---|
| 4978 Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 7.2% |
| Market Average Movement | 3.7% |
| 10% most volatile stocks in JP Market | 7.9% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 4978's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4978's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 99 | Shuji Yokoyama | www.reprocell.com |
ReproCELL Incorporated provides stem cell research and drug discovery services in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, feeder cells, pluripotent stem cells, StemEdit gene edited iPSCs, mesenchymal stem cells (MSCs), and new immortalized cell lines and related reagents; and iPSC-derived exosomes. The company also provides Alvetex 3D, a cell culture system; Alvetex, an advanced tissue bioengineering system; EZSPHERE Multiwell Dishes and Plates; KOKEN atelocollagen; ABLE Biott bioreactor systems; and 2mag stirrer systems.
ReproCELL Incorporated Fundamentals Summary
| 4978 fundamental statistics | |
|---|---|
| Market cap | JP¥15.06b |
| Earnings (TTM) | -JP¥279.00m |
| Revenue (TTM) | JP¥2.63b |
Is 4978 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4978 income statement (TTM) | |
|---|---|
| Revenue | JP¥2.63b |
| Cost of Revenue | JP¥1.30b |
| Gross Profit | JP¥1.33b |
| Other Expenses | JP¥1.61b |
| Earnings | -JP¥279.00m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Feb 12, 2026
| Earnings per share (EPS) | -2.95 |
| Gross Margin | 50.49% |
| Net Profit Margin | -10.60% |
| Debt/Equity Ratio | 0% |
How did 4978 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/07 22:53 |
| End of Day Share Price | 2026/02/06 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ReproCELL Incorporated is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Akinori Ueda | Goldman Sachs |